Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Tuberculosis is relatively scarce in Canada and other developed Western countries, but is estimated by the World Health Organization to infect as many as nine million people worldwide and kill upward of one million each year. Only babies born in Nunavut are vaccinated, because of the high rate of tuberculosis there.

iSTOCKPHOTO

A drug intended to boost the immunity provided by the tuberculosis vaccine is being tested at McMaster University and has been found safe for use in humans, but not yet proven effective, according to a new study.

While the booster is many years and clinical trials away from being approved for mass production, the finding offers some hope for the global fight against tuberculosis and follows news in recent weeks that a New Brunswick university student and a person at an Ontario high school were infected with the virus.

"There's the potential to dramatically change the course of TB," said the lead author of the study, Fiona Smaill, chair of pathology and molecular medicine at the Michael G. DeGroote School of Medicine at McMaster in Hamilton.

Story continues below advertisement

Tuberculosis is relatively rare in Canada and other developed Western countries, but is estimated by the World Health Organization to infect as many as nine million people worldwide and kill upward of one million each year. No one in Canada is vaccinated any more except babies born in Nunavut, which has a high rate of tuberculosis.

The current vaccine, known as Bacille Calmette-Guérin, or BCG, is routinely given to infants in countries with high rates of tuberculosis and shields them well. But its efficacy wanes over time.

Scientists have spent decades searching for a more effective vaccine or a booster to enhance the protective qualities of BCG.

The McMaster study was a first-phase clinical trial, which examined whether the drug could be tolerated by humans and could engage the immune system. The trial began in 2009 with 24 healthy people, half of whom had been vaccinated with BCG.

The booster's effectiveness will be determined in additional clinical trials that Dr. Smaill anticipated would take place over the next eight or more years.

Still, the booster – known as AdHu5Ag85A and based on a genetically modified cold virus – has been shown to work in mice, guinea pigs and goats, according to the study, which was published online on Wednesday in the journal Science Translational Medicine.

Dr. Smaill said her team has approached Aeras, a biotechnology not-for-profit corporation that invests in TB vaccine advancement, for funds to continue research. A spokesperson for Aeras was unable to comment immediately.

Story continues below advertisement

A dozen TB vaccines or boosters are now in clinical trials around the world, according to the World Health Organization.

For years, the most promising was one developed by researchers at Oxford University in Britain. But a clinical trial involving nearly 3,000 healthy babies in South Africa determined the vaccine was no more effective than BCG, which has been in use since 1921.

On Tuesday, officials from health advocacy groups including the World Health Organization, UNICEF, and the U.S. Centers for Disease Control and Prevention announced a strategy to eradicate tuberculosis in children. They estimated implementing it would cost $120-million per year and are searching for funding.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies